Snowdome is proud to share that 372 Australian blood cancer patients have gained access to new, cutting-edge therapies since Snowdome formed in 2010.
Over the past eight years, Snowdome has supported epigenetic research and supporting activities that increase the availability of epigenetic clinical trials for patients with blood cancers. This support was via funding grants with the Victorian Epigenetic Group (VEG), a consortium of world-class researchers from Peter MacCallum Cancer Centre, Alfred Hospital, Ludwig Institute, Austin Hospital, The Royal Melbourne Hospital, Murdoch Children’s Research Institute, The Royal Children’s Hospital, Barwon Health, St Vincent’s Hospital, Monash Medical Centre, Cabrini Health and Box Hill Hospital. To date, Snowdome has funded essential infrastructure positions such as:
- Research Fellows to develop and oversee clinical trials;
- Clinical Trials Research Nurse to increase accrual into clinical trials;
- Research Scientist to better understand drugs that might be used in clinical trials; and
- Research Project Managers & Clinical Trials Managers to coordinate clinical trials.
In 2014, Snowdome extended its funding focus and was instrumental in establishing the Centre of Research Excellence (CRE) in Myeloma. The CRE model is a proven way to accelerate the development of new therapies based on international experience and will lead to more patients gaining access to novel therapies. In the last 12 months, Snowdome has committed over $3 million to the CRE-Myeloma to support ‘personalised genetic medicine’.
We look forward to keeping you updated on our progress in these innovative areas of blood cancer research.